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Objectives The aim of this prospective study was to evaluate the home monitoring with a 
rapid fecal calprotectin test combined with a symptom questionnaire in patients with colonic 
IBD in real-life setting. 
Methods We randomized 180 patients with colonic IBD in a study or a control group. The 
home monitoring patients performed the fecal calprotectin test and filled in a symptom 
questionnaire every second month and in cases with increasing symptoms. The control 
patients filled in the symptom questionnaire at baseline and at 6 and 12 months as well as for 
the appointment at the outpatient clinic. The study duration was 12 months.  
Results The patient adherence to the self-monitoring program was low. Patients with a higher 
disease burden were more adherent than patients with better health-related quality of life, but 
otherwise there were no significant factors predicting the adherence. The home monitoring 
patients had fewer contacts with the outpatient clinic, but the disease course between the 
home monitoring and the control group were similar. 
Conclusions The self-monitoring of IBD activity with a combination of a rapid fecal 
calprotectin home test and a symptom questionnaire provides an option for individualized 
care for IBD patients. However, the adherence to the self-monitoring program remains a 
challenge.  
 






Traditionally, the treatment and monitoring of inflammatory bowel disease (IBD) has been 
based on scheduled visits to an outpatient clinic. The increasing number of IBD patients 1 2 
results in the need for new monitoring and treatment strategies. In recent studies, self-
monitoring of IBD has shown to be feasible. 3 4 5   
 
Fecal calprotectin (FC) is the most used non-invasive method for monitoring inflammatory 
activity in IBD. 6 7 8 9 To make the fecal testing more feasible, several rapid FC tests have 
been developed and validated. 10 11 12    
 
Previously, we validated a symptom questionnaire for monitoring IBD, suitable for both UC 
and CD. 13 The clinical activity of the disease was determined with 6 questions concerning 
IBD symptoms during the last week: general well-being, abdominal pain, bowel movements 
at daytime and night-time, presence of blood in stools, and the impact of the IBD on daily life 
assessed by the VAS (visual analog scale).13 
 
The aim of this study was to evaluate the feasibility of a self-monitoring strategy using a 
rapid FC test and a symptom questionnaire in patients with colonic IBD.  
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Materials and methods 
 
Between April 2015 and December 2016, adult patients with colonic IBD from Helsinki 
University Hospital, Finland, were enrolled. Exclusion criteria were extensive colon resection 
or colectomy. Patients were randomized with closed envelopes in blocks of ten into the home 
monitoring group and control group (1:1). Patients were not stratified with the IBD subtype, 
disease severity or medication. The study period was 12 months.  
 
Patients in the home monitoring group were instructed to perform a semi-quantitative FC test 
with cut-offs of FC <50 µg/g, 50-200 µg/g and >200 µg/g (Prevent ID CalDetect, Preventis, 
Immunodiagnostics AG, Germany) 12 and to fill in a symptom questionnaire 13 and a health-
related quality of life questionnaire (15D-questionnaire) 14 sent by e-mail every other month 
and with increasing of the symptoms. They reported the results to the nurse by simply filling 
in the attached documents. When performing the home test, they also provided a stool sample 
to the clinical laboratory for measuring the FC with an ELISA test. For analysis, the ELISA 
FC results were divided with the same cut-offs as the CalDetect results. In addition, FC was 
measured centrally using the CalDetect.  
 
The control patients filled in the symptom questionnaire and the 15D-questionnaire at 





For analysis, the symptom questionnaire was divided into two parts: the patient-reported 
symptoms (symptom score) (scale 0-15 points, higher score worse), and the influence of the 
disease in daily life, measured by VAS (scale 1-7, higher score worse). Remission was 
defined as the symptom score of 0-3 points, and a change of ≥2 points was considered 
clinically significant. 13 A change of ≥0.03 in the total 15D score (scale 0-1, lower score 
worse) was considered clinically important. 14 15  
 
At the beginning of the study, the patients got the schedule of the study and training about the 
study protocol and the FC testing. Patients were not reminded of performing the stool tests or 
filling in the questionnaires, but they were advised to contact the nurse by phone or e-mail if 
they had problems concerning their bowel disease (alarming symptoms; IBD symptoms and 
the CalDetect-result >200µg/g in two consecutive measurements performed in two days 
interval; or the result of the symptom questionnaire ≥ 2 points higher than the previous 
result). After the end of the study, patients were asked their opinion about study settings.  
 
Statistical analysis 
The Mann-Whitney U and the Kruskall-Wallis tests served to analyze differences between 
groups for continuous and ordinal variables. The Fisher’s exact tests were used to analyze 
differences in dichotomous variables or in variables with nominal categories. The Wilcoxon 
signed rank tests served to determine differences between two tests performed on the same 
sample. The Spearman’s rank correlation coefficient was calculated to assess correlations 
between the two variables. A Kaplan-Meier survival curve was drawn to analyze the 
compliance of the two groups of patients. Results were analyzed with IBM SPSS (v.24, IBM 






All patients provided their written informed consent prior to enrolment. The Ethics 








Of the 322 patients invited to the study, 142 patients (44 %) refused to participate or never 
responded. The eligible 180 patients were randomized into the home monitoring group (89 
patients) or control group (91 patients) (Figure 1).  
 
Patient adherence 
In total, 63 home monitoring patients and 60 control patients (69 % of the included 180 
patients) started the study, and were included in the analysis. The demographic data of the 
patients are presented in Table 1. In the home monitoring group, 24 patients (38 %) and in the 
controls 12 patients (20 %) continued the study for 12 months (p=0.001) (Figure 2). The 
median duration of the study was 10 months for the home monitoring patients and 5.5 months 
for the controls (p<0.001). Those who participated in the study for 6 months or more, were 
considered as compliants (71 % in the home monitoring group and 46 % in the controls, 
p=0.005), and the rest as non-compliants. Compliant patients were older than non-compliants 
(mean age 38 years vs 31 years, respectively, 95 % CI 35-40 and 26-36, p=0.013), but 
otherwise there were no differences between compliants and non-compliants stratified with 
the IBD-subtype, sex, age-group, disease duration or medication.  
 
Symptoms 
During the study, 428 symptom questionnaires were completed (mean 3 
questionnaires/patient). The median symptom score was 1 point (range 0-11), and the median 
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VAS was 2 (range 1-7). The baseline VAS was higher in those patients who continued the 
study compared to those who dropped out after the baseline (mean 2.58 (95 % CI 2.17-2.98) 
and 2.08 (1.81-2.42) respectively, p=0.058). Compliant home monitoring patients reported 
higher baseline VAS than non-compliant patients (mean 2.73 (95 % CI 0.915-0.959) and 1.81 
(0.886-0.951) respectively, p=0.019). The results of the symptom scores, VAS scores and 
15D scores are presented in Table 2.  
 
Health-related quality of life  
A total of 420 15D-questionnaires were completed (mean 3 questionnaires/patient). There   




During the study, 63 home monitoring patients performed 301 CalDetect-tests (mean 5 
tests/patient) (Table 4, supplemental material). The median result was FC 50-200 µg/g, and 
there was no significant difference in the baseline results between compliants and non-
compliants (p=0.630). During the study, 10 patients (16 %) performed 12 extra CalDetect-
tests because of worsening symptoms and, as expected, the FC in these tests was higher (FC 
>200 µg/g in 60 % of extra tests vs. in 27 % of the routine tests). At the study end, there were 





The home monitoring patients sent 264 stool samples to the laboratory, compared to 310 tests 
performed at home. The median ELISA FC of the home monitoring patients was 67 µg/g 
(range 1-3834). The correlation between ELISA FC and CalDetect made in the laboratory 
was statistically significant and slightly better than the correlation between ELISA FC and 
CalDetect made by patients at home (r=0.740 and 0.417 respectively, p<0.05).  
 
Disease course and activity 
The numbers of relapses, contacts to the outpatient clinic, laboratory visits and 
hospitalizations are presented in Table 3. Disease activity was similar in both groups. During 
the study, 46 patients fulfilled the criteria for clinically active disease (25 in the home 
monitoring and 21 in the control group). Twenty-three patients had more than 2 points’ raise 
in the two consecutive symptom scores, which was regarded as clinically significant; 14 in 
the home monitoring group and 9 in the control group. As many as 17 of 24 patients (71 %) 
who filled in extra symptom questionnaires because of worsening symptoms had a symptom 
score < 3 points, indicating clinical remission despite the symptoms.  
 
Visits, phone calls and e-mails 
There were 281 visits to the outpatient clinic (mean 2.3 visits/patient, range 0-7). In the 
control group, 40 % of the patients had more than 2 visits, compared to 24 % in the home 
monitoring group (p=0.05). Sixty-four patients made 182 phone calls to the outpatient clinic 
(mean 4 phone calls/patient, range 1-14). Of all phone calls, 66 (24 %) were made because of 
worsening symptoms (no statistical difference between the groups).  
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In total, 54 patients sent 210 e-mails (mean 3.8 mails/patient, range 1-24), the controls 
sending more e-mails per patient than home monitoring patients (mean 4.9 and 2.8, 
respectively, p=0.180).  
 
Visits to the laboratory  
There were 803 laboratory visits (mean 6.5 visits/patient, range 1-20). Of all visits, 87 % 
were planned at inclusion, mainly for drug safety control, and 13 % were extra visits due to 
the symptoms. The numbers of the laboratory visits were comparable between the groups 
(392 in home monitoring group and 411 in controls, p=0.636), but extra tests were more 
common in the home monitoring (61) than in the control group (42) (p=0.024). 
 
Patient opinions on home-monitoring  
After completing the follow-up, questionnaires on patient opinions on home-monitoring were 
sent by e-mail to all the 123 patients who started the study, including the control patients as 
well. No reminders were sent. Only 25 patients responded, 16 (64%) being from the home 
monitoring group. Of the respondents, 56 % had completed the 12 months follow-up.  More 
than 80 % of the respondents considered the self-monitoring strategy and the questionnaires 
simple. Most of the patients (71 %) preferred e-mail contacts to the outpatient clinic instead 
of phone contacts, and 66 % wanted to continue the use of e-mail in non-urgent matters. The 
views were similar in the home monitoring and control groups.  None of the home monitoring 
patients considered the fecal testing uncomfortable. Eighteen percent considered the technical 
performance of the test complicated, and 46 % considered the interpretation of the test results 
difficult. More than half of the patients (57 %) wished to continue the fecal home testing in 





The primary aim of this study was to evaluate the feasibility of the self-monitoring strategy in 
a real-life setting. The percentage of patients (44 %) who never responded to the invitation 
letter was comparable with earlier studies with up to 35-50 % of patients not reached. 3 16 The 
drop-out rate in our study was higher than in some earlier studies (71 % in total; 62 % in the 
home monitoring group and 80 % in the controls), 4 17 18 but it was in line with the large 
feasibility trial showing up to 74 % drop-out rates. 19  
 
The baseline influence of IBD in daily life was higher in the patients who continued the study 
for more than 6 months than in those who dropped out after the baseline, even if there was no 
difference in the baseline FC or the symptom score. It seems that the patients having a higher 
disease burden are more adherent and motivated to do the home-monitoring than those 
patients who do not experience any problems or inconvenience with their disease.  
 
We could not demonstrate any differences in the disease activity between the home 
monitoring and control patients, which can be due to the low number of compliant patients. 
Moreover, even if the patients made phone calls and e-mails because of worsening 
symptoms, they had not filled in the symptom score and therefore did not fulfill the defined 
criteria for clinically active disease.  
 
The FC level measured with the home test was slightly lower at the end of the study than at 
the baseline, but this did not reach clinical significance. The control patients sent more e-
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mails concerning their disease and had more appointments at the outpatient clinic than the 
home monitoring patients, which proves that home-monitoring strategy may aid in resourcing 
health-care.  
 
We are aware of the limitations of our study. We did not have the possibility to construct an 
internet portal designed for this purpose, but patients sent the questionnaires and the results of 
the FC tests to the nurse by e-mail, which many of them found unpractical. Half of the 
patients found the results of the semi-quantitative FC test difficult to interpret.  
 
To the best of our knowledge, our study is among the first studies to evaluate the home 
monitoring strategy in a real-life setting in all subtypes of colonic IBD regardless of the 
disease severity or medication. In previous studies, the self-monitoring of IBD has shown to 
be a promising means for the more patient-centered follow-up than routine visits to the 
outpatient clinic. However, we still do not know which patients are suitable for self-
monitoring. The adherence to the self-monitoring program remains a challenge, and we could 
not find any factors predicting the adherence. The easy accessibility of the monitoring 
program and simultaneous feedback of the disease activity may increase patient motivation 
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Gender M, n (%) 58 (47) 22 (49) 8 (44) 13 (46) 15 (47) 






























Disease duration,  
years, n (%)  
< 1  
2-10  
11-20  















































































1.2 (0-8) 1.4 (0-4) 0.9 (0-3) 1.2 (0-6) 1.4 (0-8) 
Baseline VAS, 
median (range) c 
2.2 (1-7) 2.7 (1-7) a 1.8 (1-5) a 2.2 (1-5) 3.0 (1-7) 
Baseline 15D score, 













VAS=visual analog scale 
a p<0.05 
b scale 0-15, higher score worse 
c scale 1-7, higher score worse  





Table 2. Results of the symptom questionnaire and health related quality of life  
Time, 
months 
symptom score, mean 
(scale 0-15, higher 
worse)  
VAS, mean 
(scale 0-7, higher worse)  
15D score, mean 
















0 1.0 (62) 1.3 (59) 2.2 (62) 2.5 (59) 0.926 (62) 0.929 (58) 
2 1.2 (47) 2.2 (19) 2.2 (47) 2.1 (19) 0.941 (33) 0.941 (27) 
4 1.3 (37) 1.0 (14) 2.2 (37) 1.6 (14) 0.943 (28) 0.945 (23) 
6 0.9 (35) 1.1 (21) 1.9 (35) 1.9 (21) 0.937 (31) 0.935 (26) 
8 1.3 (32) 1.1 (14) 1.9 (32) 1.9 (14) 0.934 (23) 0.940 (19) 
10 1.0 (26) 0.7 (10) 2.0 (26) 2.0 (10) 0.931 (19) 0.922 (16) 
12 0.9 (19) 0.8 (9) 2.0 (19) 2.0 (9) 0.919 (15) 0.929 (11) 
extra 1 3.2 (4) 2.9 (11) 3.3 (4) 3.2 (11) 0.908 (9) 0.908 (10) 
extra 2 1.5 (2) 1.3 (5) 2.0 (2) 2.2 (5) 0.965 (2) 0.912 (4) 
extra 3 - 3.0 (2) - 3.0 (2) 0.929 (1) 0.909 (2) 
 
The home monitoring patients completed the questionnaires in every other month, and the 
control group at the baseline, 6 months, and 12 months, and at the appointment to the 




Table 3. The influence of the home-monitoring to the disease course.  
 
 






Relapses (according to 
the symptom score) 
46 25 21 0.521 
Hospitalizations 6 4 a 1 - 
Outpatient clinic visits 
(n=119 patients) 






























E-mails (n=54 patients) 










Phone calls (n=64 
patients) 




































322 patients were invited 
180 randomized 
142 refused/not reached 
91 control patients 89 home monitoring patients  
31 never attended 26 never attended
 32 withdrew before 
6 months 
18 withdrew before 
6 months 
28 control patients completed 
6 months follow-up 
 45 home monitoring 
patients completed 6 months 
follow-up 
 16 withdrew before 
12 months 
21 withdrew before 
12 months 
24 home monitoring 
patients completed 12 
months follow-up 
12 control patients completed 
12 months follow-up 
63 home monitoring patients 
started the follow-up 




Figure 2. Compliance of all the included patients (Kaplan-Meier curve) 
 
 
 
 
